Zacks Research Has Weak Outlook for Cytosorbents Q1 Earnings

Cytosorbents Corporation (NASDAQ:CTSO) – Equities research analysts at Zacks Research dropped their Q1 2026 EPS estimates for Cytosorbents in a report issued on Monday, April 6th. Zacks Research analyst T. Kerr now expects that the medical research company will earn ($0.06) per share for the quarter, down from their prior forecast of ($0.03). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. Zacks Research also issued estimates for Cytosorbents’ Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.19) EPS.

Several other analysts have also commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a research report on Friday, January 9th. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a research report on Thursday, March 26th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $5.38.

Cytosorbents Trading Up 3.4%

Shares of Cytosorbents stock opened at $0.61 on Wednesday. The company has a debt-to-equity ratio of 1.61, a current ratio of 2.11 and a quick ratio of 1.71. The firm has a fifty day moving average price of $0.67 and a 200 day moving average price of $0.73. Cytosorbents has a 1 year low of $0.50 and a 1 year high of $1.39. The stock has a market cap of $38.24 million, a PE ratio of -4.69 and a beta of 1.47.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Wednesday, March 25th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). The company had revenue of $9.23 million during the quarter, compared to analysts’ expectations of $9.22 million. Cytosorbents had a negative return on equity of 131.86% and a negative net margin of 22.12%.

Hedge Funds Weigh In On Cytosorbents

Institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. boosted its position in Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after acquiring an additional 37,519 shares during the last quarter. Citadel Advisors LLC raised its stake in Cytosorbents by 127.3% during the third quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after purchasing an additional 36,790 shares during the period. GSA Capital Partners LLP purchased a new position in Cytosorbents during the third quarter worth about $105,000. CIBC Bancorp USA Inc. purchased a new position in Cytosorbents during the third quarter worth about $161,000. Finally, CM Management LLC raised its stake in Cytosorbents by 3.1% during the third quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock worth $1,203,000 after purchasing an additional 38,128 shares during the period. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.